Baricitinib Phase 3 Clinical Trial begins: For hospitalized COVID-19 patients
by Press Release from Outbreak News Today on (#54MEB)
Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with COVID-19. Baricitinib, marketed as OLUMIANT(R), is approved in 70 countries as a treatment for adults [...]
The post Baricitinib Phase 3 Clinical Trial begins: For hospitalized COVID-19 patients appeared first on Outbreak News Today.